Abstract PO3-13-09: Personalized ctDNA testing for detection of molecular residual disease in patients with localized HR+ breast cancer: temporal dynamics and impact on clinical outcomes
Arielle J. Medford(Harvard University), Aditya Bardia(UCLA Health), Rachel O. Abelman(Massachusetts General Hospital), Beverly Moy(Global Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Yael Bar(Tel Aviv University), Minetta C. Liu(Mayo Clinic), Amy Comander(Harvard University), Elyssa N. Denault(Massachusetts General Hospital), Zanta Ephrem(Massachusetts General Hospital), J. T. A. Knape(Massachusetts General Hospital), Douglas S. Micalizzi(Massachusetts General Hospital), Angel Rodríguez(Natera (United States)), Steven J. Isakoff(Harvard University)
Cited by 1
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k